MicroRNA-29b-3p Attenuates Diabetic Nephropathy in Mice by Modifying EZH2

Overview

Journal Hormones (Athens)

Specialty Endocrinology

Date 2023 Jan 24

PMID 36692688

Authors

Yurong Zhao

Dandan Li

Ping Zhou

Yujie Zhao

Jinsong Kuang

Affiliations

Soon will be listed here.

Abstract

Objective: Diabetic nephropathy (DN) is the leading cause of end-stage renal disease around the world. This study investigated the role of microRNA (miR)-29b-3p in DN and the mechanism of the miR-29b-3p/EZH2 axis in DN.

Methods: Peripheral blood samples of DN patients were collected and miR-29b-3p and EZH2 expression levels were evaluated using RT-qPCR. DN mouse models were successfully established, and then treated with miR-29b-3p overexpression or EZH2 silence. IL-1β, IL-6, and TNF-α levels were assessed by ELISA. Blood glucose, serum creatinine (Scr), 24-h urine volume, 24-h urine protein, and blood urea nitrogen (BUN) levels were examined by automatic biochemical analyzer detection. HE staining was performed to observe the renal histopathology, and TUNEL staining was implemented to test apoptosis in renal tissues. The binding relationship between miR-29b-3p and EZH2 was validated by using a bioinformatics website and dual luciferase reporter gene assay.

Results: miR-29b-3p was lowly expressed, and EZH2 was highly expressed in patients with DN. Overexpressing miR-29b-3p or silencing EZH2 attenuated renal dysfunction, suppressed inflammation and apoptosis, and relieved renal injuries in mice with DN. miR-29b-3p inhibited EZH2, and miR-29b-3p overexpression mitigated renal injuries in DN mice by repressing EZH2.

Conclusion: miR-29b-3p suppresses EZH2 expression thereby inhibiting the progression of DN in mice.

Citing Articles

MiR-29b Alleviates High Glucose-induced Inflammation and Apoptosis in Podocytes by Down-regulating PRKAB2.

Du H, Wang Y, Zhu Y, Li X, Zhu T, Wu Q Endocr Metab Immune Disord Drug Targets. 2024; 24(8):981-990.

PMID: 38204237 PMC: 11275309. DOI: 10.2174/0118715303267375231204103200.

References

Liu D, Zheng W, Pan S, Liu Z . Concise review: current trends on applications of stem cells in diabetic nephropathy. Cell Death Dis. 2020; 11(11):1000. PMC: 7680458. DOI: 10.1038/s41419-020-03206-1. View

Bonner R, Albajrami O, Hudspeth J, Upadhyay A . Diabetic Kidney Disease. Prim Care. 2020; 47(4):645-659. DOI: 10.1016/j.pop.2020.08.004. View

Selby N, Taal M . An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines. Diabetes Obes Metab. 2020; 22 Suppl 1:3-15. DOI: 10.1111/dom.14007. View

Leoncini G, Viazzi F, De Cosmo S, Russo G, Fioretto P, Pontremoli R . Blood pressure reduction and RAAS inhibition in diabetic kidney disease: therapeutic potentials and limitations. J Nephrol. 2020; 33(5):949-963. PMC: 7557495. DOI: 10.1007/s40620-020-00803-3. View

Yarahmadi A, Shahrokhi S, Mostafavi-Pour Z, Azarpira N . MicroRNAs in diabetic nephropathy: From molecular mechanisms to new therapeutic targets of treatment. Biochem Pharmacol. 2020; 189:114301. DOI: 10.1016/j.bcp.2020.114301. View

Sankrityayan H, Kulkarni Y, Gaikwad A . Diabetic nephropathy: The regulatory interplay between epigenetics and microRNAs. Pharmacol Res. 2019; 141:574-585. DOI: 10.1016/j.phrs.2019.01.043. View

Gondaliya P, P Dasare A, Jash K, Kumar Tekade R, Srivastava A, Kalia K . miR-29b attenuates histone deacetylase-4 mediated podocyte dysfunction and renal fibrosis in diabetic nephropathy. J Diabetes Metab Disord. 2020; 19(1):13-27. PMC: 7270417. DOI: 10.1007/s40200-019-00469-0. View

Xing L, Wang H, Yin P, Liu Y, Chi Y, Wang Y . Reduced mir-29b-3p expression up-regulate CDK6 and contributes to IgA nephropathy. Int J Clin Exp Med. 2015; 7(12):5275-81. PMC: 4307478. View

Zhang X, Zhao X, Fiskus W, Lin J, Lwin T, Rao R . Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas. Cancer Cell. 2012; 22(4):506-523. PMC: 3973134. DOI: 10.1016/j.ccr.2012.09.003. View

10.

Li Z, Yu Z, Meng X, Yu P . LncRNA LINC00968 accelerates the proliferation and fibrosis of diabetic nephropathy by epigenetically repressing p21 via recruiting EZH2. Biochem Biophys Res Commun. 2018; 504(2):499-504. DOI: 10.1016/j.bbrc.2018.08.048. View

11.

Komers R, Mar D, Denisenko O, Xu B, Oyama T, Bomsztyk K . Epigenetic changes in renal genes dysregulated in mouse and rat models of type 1 diabetes. Lab Invest. 2013; 93(5):543-52. DOI: 10.1038/labinvest.2013.47. View

12.

Wan J, Hou X, Zhou Z, Geng J, Tian J, Bai X . WT1 ameliorates podocyte injury via repression of EZH2/β-catenin pathway in diabetic nephropathy. Free Radic Biol Med. 2017; 108:280-299. DOI: 10.1016/j.freeradbiomed.2017.03.012. View

13.

Zhou X, Zang X, Guan Y, Tolbert T, Zhao T, Bayliss G . Targeting enhancer of zeste homolog 2 protects against acute kidney injury. Cell Death Dis. 2018; 9(11):1067. PMC: 6195522. DOI: 10.1038/s41419-018-1012-0. View

14.

Li T, Yu C, Zhuang S . Histone Methyltransferase EZH2: A Potential Therapeutic Target for Kidney Diseases. Front Physiol. 2021; 12:640700. PMC: 7930071. DOI: 10.3389/fphys.2021.640700. View

15.

Li Y, Yu W, Xiong H, Yuan F . Circ_0000181 regulates miR-667-5p/NLRC4 axis to promote pyroptosis progression in diabetic nephropathy. Sci Rep. 2022; 12(1):11994. PMC: 9283475. DOI: 10.1038/s41598-022-15607-7. View

16.

Zhang L, Zhao S, Zhu Y . Long noncoding RNA growth arrest-specific transcript 5 alleviates renal fibrosis in diabetic nephropathy by downregulating matrix metalloproteinase 9 through recruitment of enhancer of zeste homolog 2. FASEB J. 2020; 34(2):2703-2714. DOI: 10.1096/fj.201901380RR. View

17.

Ying Li H, Oh Y, Choi J, Jung J, Jun H . Blocking lysophosphatidic acid receptor 1 signaling inhibits diabetic nephropathy in db/db mice. Kidney Int. 2017; 91(6):1362-1373. DOI: 10.1016/j.kint.2016.11.010. View

18.

Chen H, Jin G . Downregulation of Salusin-β protects renal tubular epithelial cells against high glucose-induced inflammation, oxidative stress, apoptosis and lipid accumulation via suppressing miR-155-5p. Bioengineered. 2021; 12(1):6155-6165. PMC: 8806677. DOI: 10.1080/21655979.2021.1972900. View

19.

Zhang S, Wang H, Liu Y, Yang W, Liu J, Han Y . Tacrolimus ameliorates tubulointerstitial inflammation in diabetic nephropathy via inhibiting the NFATc1/TRPC6 pathway. J Cell Mol Med. 2020; 24(17):9810-9824. PMC: 7520323. DOI: 10.1111/jcmm.15562. View

20.

Luo W, Chen X, Ye L, Chen X, Jia W, Zhao Y . Kaempferol attenuates streptozotocin-induced diabetic nephropathy by downregulating TRAF6 expression: The role of TRAF6 in diabetic nephropathy. J Ethnopharmacol. 2020; 268:113553. DOI: 10.1016/j.jep.2020.113553. View